Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sonali Khond

Internal Medicine North Easton, MA Medical Doctor

NPI 1023089885 CMS profile 272824

184 Lincoln St, North Easton, MA 02356

Open in the dashboard

General payments

$6,516

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sonali Khond of North Easton, MA is reported in the CMS Open Payments database as having received $6,516 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,698 116
2024 General $2,975 120
2023 General $748 32
2022 General $55 1
2019 General $40 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sonali Khond
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sonali Khond were reported at $2,698. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sonali Khond Internal Medicine median Middle half National median
2019 $40 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $55 $141 $42–$496 $149
2023 $748 $149 $45–$519 $160
2024 $2,975 $154 $47–$537 $164
2025 $2,698 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $957 32 payments
  2. AstraZeneca Pharmaceuticals LP $938 29 payments
  3. Lilly USA, LLC $733 35 payments
  4. AbbVie, Inc. $377 17 payments
  5. Pfizer Inc. $342 18 payments
  6. Novartis Pharmaceuticals Corporation $304 17 payments
  7. Eisai Inc. $254 8 payments
  8. Amgen Inc. $247 13 payments
  9. Sumitomo Pharma America, Inc. $244 12 payments
  10. Abbott Laboratories $202 6 payments
  11. Other $1,918 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,516 270 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $601 18 payments
  2. Wegovy $560 19 payments
  3. JARDIANCE $304 14 payments
  4. LEQVIO $304 17 payments
  5. ZEPBOUND $303 16 payments
  6. Leqembi $297 10 payments
  7. Ozempic $261 8 payments
  8. UBRELVY $252 10 payments
  9. EVENITY $247 13 payments
  10. GEMTESA $244 12 payments
  11. Other $4,090 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

4,658

Median for Internal Medicine: 777

Drug cost

$317,034

Median for Internal Medicine: $73,373

Branded share of claims

17.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 91 $82,428
Ozempic Semaglutide Brand 50 $49,867
Jardiance Empagliflozin Brand 21 $27,752
Xarelto Rivaroxaban Brand 21 $20,632
Rybelsus Semaglutide Brand 19 $20,037
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $15,610
Farxiga Dapagliflozin Propanediol Brand 17 $12,767
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 45 $6,322
Oxycontin Oxycodone Hcl Brand 11 $6,244
Breo Ellipta Fluticasone/Vilanterol Brand 15 $6,012

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$96,349

Of which drugs: $14,300

Medicare patients

225

Average age 75

Services billed

1,436

162 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 28%
Ischemic heart disease 19%
Atrial fibrillation 19%
Depression 18%
Chronic kidney disease 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 33 33 $9,574
Vaccine for influenza for injection into muscle 90653 Office 53 53 $4,225

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $373
$373 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $267
$267 — —
Leqembi
  • Eisai Inc. $159
  • Biogen, Inc. $24
$183 — —
UBRELVY
  • AbbVie, Inc. $179
$179 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record